NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

Mark R. Gilbert; Stephanie L. Pugh; Ken Aldape; A. Gregory Sorensen; Tom Mikkelsen; Marta Penas-Prado; Felix Bokstein; Young Kwok; R. Jeffrey Lee; Minesh Mehta

doi:10.1007/s11060-016-2288-5

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

Mark R. Gilbert, Stephanie L. Pugh, Ken Aldape, A. Gregory Sorensen, Tom Mikkelsen, Marta Penas-Prado, Felix Bokstein, Young Kwok, R. Jeffrey Lee, Minesh Mehta

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	131
DOIs	https://doi.org/10.1007/s11060-016-2288-5
State	Published - Jan 1 2017

Disciplines

Anesthesiology
Physical Therapy
Medicine and Health Sciences
Surgery
Pathology

Access to Document

10.1007/s11060-016-2288-5License: Unspecified

Cite this

@article{fd83850beeef4275862c313671991c2c,

title = "NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma",

author = "Gilbert, {Mark R.} and Pugh, {Stephanie L.} and Ken Aldape and Sorensen, {A. Gregory} and Tom Mikkelsen and Marta Penas-Prado and Felix Bokstein and Young Kwok and Lee, {R. Jeffrey} and Minesh Mehta",

note = "Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. Eligibility included age ≥18, recurrent or progressive GBM after standard chemoradiation.",

year = "2017",

month = jan,

day = "1",

doi = "10.1007/s11060-016-2288-5",

language = "American English",

volume = "131",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

AU - Gilbert, Mark R.

AU - Pugh, Stephanie L.

AU - Aldape, Ken

AU - Sorensen, A. Gregory

AU - Mikkelsen, Tom

AU - Penas-Prado, Marta

AU - Bokstein, Felix

AU - Kwok, Young

AU - Lee, R. Jeffrey

AU - Mehta, Minesh

N1 - Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. Eligibility included age ≥18, recurrent or progressive GBM after standard chemoradiation.

PY - 2017/1/1

Y1 - 2017/1/1

UR - https://link.springer.com/article/10.1007/s11060-016-2288-5

U2 - 10.1007/s11060-016-2288-5

DO - 10.1007/s11060-016-2288-5

M3 - Article

VL - 131

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

Disciplines

Access to Document

Other files and links

Cite this